Literature DB >> 28585582

Factors associated with mortality to drug-resistant tuberculosis and their programmatic management in treatment centres of Punjab, Pakistan.

Shamsa Kanwal1, Abdul Majeed Akhtar1, Anzar Ahmed1.   

Abstract

OBJECTIVE: To describe the characteristics and assess the factors of mortality in drug-resistant tuberculosis patients.
METHODS: This retrospective study was conducted at 11 programmatic management of drug-resistant tuberculosis centres located in different cities of the Punjab province of Pakistan, and comprised record of patients with drug-resistant tuberculosis from January 2010 to September 2015. Data was retrieved from patient medical records using electronic nominal review system of the provincial tuberculosis control programme. Cox's proportional hazards model was performed to identify the factors for death. SPSS 17 was used for data analysis.
RESULTS: Of the 1,136 patients, 472(41.5%) died during treatment and 664(58.5%) were declared cured or their treatment was completed. Of those who expired, 97(20.6%) expired within 3 months of the start of the treatment. Men had higher rates of death which was not significantly associated with the drug-resistant tuberculosis mortality (p>0.05).
CONCLUSIONS: The number of patients who died from drug-resistant tuberculosis treatment was relatively high.

Entities:  

Keywords:  Drug-resistant tuberculosis, Mortality, PMDT sites, ENRS.

Mesh:

Substances:

Year:  2017        PMID: 28585582

Source DB:  PubMed          Journal:  J Pak Med Assoc        ISSN: 0030-9982            Impact factor:   0.781


  2 in total

1.  Strengthening the response to drug-resistant TB in Pakistan: a practice theory-informed approach.

Authors:  S Abbas; M Kermode; S Kane
Journal:  Public Health Action       Date:  2020-12-21

2.  Incidence and predictors of mortality among persons receiving second-line tuberculosis treatment in sub-Saharan Africa: A meta-analysis of 43 cohort studies.

Authors:  Dumessa Edessa; Fuad Adem; Bisrat Hagos; Mekonnen Sisay
Journal:  PLoS One       Date:  2021-12-10       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.